Organ preservation for rectal cancer

Area of Science:

• Oncology
• Surgical Gastroenterology
• Rectal Cancer Treatment

Background:

• Patient-centered goals in rectal cancer treatment prioritize organ preservation and functional maintenance.
• While sphincter-sparing surgery is often feasible for resectable rectal cancer, achieving successful intestinal continuity post-resection is influenced by various patient, tumor, surgical, and treatment-related factors.
• Population-based data indicate lower sphincter preservation rates compared to expert centers, with some cases deemed unsuitable for low anterior resection or ultralow anastomosis due to technical or oncological limitations, or potential functional compromise.

Purpose of the Study:

• To evaluate the role and outcomes of local treatment modalities for rectal cancer.
• To discuss the challenges and considerations in achieving sphincter preservation and functional recovery after rectal cancer resection.
• To highlight the trade-offs between radical resection and local excision in terms of oncological control and functional sequelae.

Main Methods:

• Review of current surgical approaches for rectal cancer, including radical resection and local excision.
• Analysis of factors influencing the feasibility and success of sphincter-sparing procedures and colo-anal anastomosis.
• Discussion of the oncological and functional outcomes associated with different treatment strategies.

Main Results:

• Radical resection with sphincter preservation is achievable for most resectable rectal cancer patients, but success is multifactorial.
• Local excision aims to reduce morbidity and functional deficits but is associated with a higher local recurrence rate compared to radical resection.
• Ultralow anastomosis, while preserving the sphincter, can lead to significant functional compromise.

Conclusions:

• Strict patient selection and informed consent regarding local recurrence risks are essential for local excision of rectal cancer.
• Local excision is a viable option for select rectal cancer patients, balancing morbidity reduction with oncological safety.
• Adjuvant therapy in conjunction with local excision, particularly for T2 lesions, warrants further investigation within clinical trials.